摘要
目的:研究肾移植术后3种免疫抑制治疗方案的性价比。方法:将同期首次行肾移植患者根据免疫抑制治疗方案不同分组,即A组:国产环孢素(田可)+麦考酚吗乙酯+泼尼松;B组:进口环孢素(新山地明)+麦考酚吗乙酯+泼尼松;C组:他克莫司(FK506)+麦考酚吗乙酯+泼尼松,每组30例,分析肾移植患者开始12个月的治疗成本和效果。结果:3组术后12个月的平均成本分别为47288、57800元和62904元,显效率分别为53.33%、56.67%、80%,成本-效果比分别为886.71、1019.94和786.3。C组疗效最佳,但成本较高,A组显效率低,但较为经济。结论:肾移植术后3种免疫抑制治疗方案成本-效果比值显示,C组最佳,A组最经济,B组的性价比较差,但还要根据患者实际病情及经济条件选择。
OBJECTIVE：To evaluate the cost-effectiveness of three immunosuppressive therapies for patients following renal transplantation.METHODS：90 patients undergoing kidney transplantation（for the first time） simultaneously were randomly assigned into 3 groups of 30 each：Group A（domestic-made CsA ＋ mycophenolate ＋ prednisone）,Group B [imported CsA（sandimmun neoral） ＋ mycophenolate ＋ prednisone] and Group C（FK506 ＋ mycophenolate ＋ prednisone）.The treatment cost and effectiveness of the three groups at 12 months after operation were analyzed.RESULTS：At 12 months,the costs of the three groups（A,B and C） Nwere 47 288,57 800 and 62 904 yuan,effectively;the remarkable effectiveness rate were 53.33%,56.67% and 80%,respectively,and the cost-effective ratios were 886.71,1 019.94 and 786.3,respectively.Group C exhibited highest curative efficacy and highest cost;Group A had lowest remarkable effectiveness rate yet it was more economical.CONCLUSION：Group C was the best one in terms of cost-effective ratio;Group A is the most economical one,while Group B had poor cost-effectiveness ratio.Finally,the choice of therapy should be based on patients＇ real state of illness and their economical condition.
出处
《中国医院用药评价与分析》
2009年第7期526-527,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
